Tag:
NIH
Latest Headlines
Latest Headlines
HIV vaccine carries its own adjuvant into clinical trials
The trial will include 48 people at four sites in the U.S., 40 receiving the vaccine at increasing doses and 8 as controls, and will check the safety of the vaccine while looking out for an immune response.
New study confirms worst fears about Merck's HIV vaccine
Five years ago Merck investigators stunned everyone working in the AIDS research field with the news that they were abruptly halting a study of a prospective HIV vaccine after the data began to make clear that it wasn't only failing to guard against the virus, but appeared to increase the risk of becoming infected.
NIH taps Genentech drug for pioneering Alzheimer's study
Researchers will test crenezumab in Colombians with a particular genetic mutation, aiming to see if the drug can stop Alzheimer's before it starts.
Genentech drug picked for pioneering $100M Alzheimer's trial
Investigators will test the drug in a region of Colombia where a particular genetic mutation is known to trigger the early onset of Alzheimer's.
NIH pumps $6M into DNA analysis for Alzheimer's plan
As GenomeWeb reports, the National Institutes of Health's National Institute on Aging has heeded the president's call for action and awarded up to $6 million for three projects that aim to analyze DNA sequencing data related to Alzheimer's.
NIH, U.S. agencies pay for nearly half of global health R&D
Uncle Sam has been a champion of backing research of global health concerns that plague populations well outside of U.S. borders, according to a study by Global Health Technologies.
Pfizer, Lilly, AstraZeneca giving NIH abandoned drugs
Three of the world's largest drug manufacturers are going to empty out their closets and turn over research on unsuccessful drugs to the National Institutes of Health.
Pharma giants offer up drug candidates for $20M NIH collaboration
The idea is simple: The drug companies will offer up their data and investigators will have a chance to explore new uses, with a set of deal templates in place to help speed the process on 20 programs.
Crazy or creative? MIT finance whiz suggests a twist on CDOs for R&D
MIT finance engineering professor Andrew Lo caused a stir this week when he expounded on an unorthodox idea.
U-M registers second stem cell line as research fight continues
University of Michigan researchers continue to resist the Republican state legislators' effort to force it to reveal how many embryos it uses for stem cell research.
